Differences in pharmacology of tumor necrosis factor (TNF) antagonists

[Differences in pharmacology of tumor necrosis factor (TNF) antagonists].

The commercially available inhibitors of TNF are constituted by two classes of molecules: the soluble receptors (Etanercept: Amgen Inc. Wyeth) and the monoclonal antibodies (Adalimumab: Abbott Laboratories and Infliximab: Centocor, Inc.). The differences in their molecular structure, mechanism of action, pharmacokinetics (PK) and pharmacodynamics (PD) are discussed, along with the differences c...

TUMOR NECROSIS FACTOR ALPHA (TNF-a)

Tumor necrosis factor alpha (TNF, TNFSF2) is an important multifunctional cytokine that regulates inflammation, host defense, immune responses, and apoptosis. TNF exists as a membrane-bound 26kDa, type II integral membrane protein, and a 17kDa soluble homotrimeric TNF that is generated via proteolytic cleavage by TNF-a converting enzyme (TACE, ADAM17). Both the membrane-bound and soluble forms ...

Evaluation of Tumor Necrosis Factor Alpha Polymorphism Frequencies in Endometriosis

Background The pro-inflammatory cytokine, tumor necrosis factor-alpha (TNF-α), is a pathogenic element for a number of disorders. Previous studies have reported that the -1031 T/C and -238 G/A polymorphisms in the promoter region of the TNF-α gene are important factors in reproductive-related disorders. One of the most common gynecological diseases of women during the reproductive years is endo...

Necrosis Factor Antagonists During Pregnancy ? ' s Safety Assessment of Tumor

Tumor Necrosis Factor (TNF) and Chemokines in Colitis-Associated Cancer

The connection between inflammation and tumorigenesis has been well established, based on a great deal of supporting evidence obtained from epidemiological, pharmacological, and genetic studies. One representative example is inflammatory bowel disease, because it is an important risk factor for the development of colon cancer. Moreover, intratumoral infiltration of inflammatory cells suggests t...